Caris Life Sciences (CAI) closed at $17.58 on November 20, 2026, down 5.2% from the previous close, on volume of 4,123,892 shares (30-day average 3,769,967).
Data as of November 20, 2026.
20-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 2, 2026 | Call Spread | 15-Jan-2730 : 35 C | 2,800 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 20, 2026. See the largest for 5, 30, 60 and 90 days
Diagnostic stocks safe from proposed crackdown on Medicare fraud
Seeking Alpha News (Tue, 17-Nov 10:41 AM ET)
Coatue Management takes new stake in Salesforce, increases Meta holdings among Q3 moves
Seeking Alpha News (Mon, 16-Nov 12:14 PM ET)
Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
PRNewswire (Wed, 4-Nov 4:05 PM ET)
CAI spotlights AI-driven cancer screening with a Jordan Spieth national commercial for Caris Detect
Market Chameleon (Mon, 19-Oct 5:15 AM ET)
PRNewswire (Mon, 19-Oct 6:31 AM ET)
Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
PRNewswire (Thu, 15-Oct 8:31 AM ET)
PRNewswire (Wed, 14-Oct 8:31 AM ET)
PRNewswire (Tue, 8-Sep 6:30 AM ET)
PRNewswire (Wed, 2-Sep 8:31 AM ET)
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Caris Life Sciences trades on the NASDAQ stock market under the symbol CAI.
As of November 20, 2026, CAI stock price declined to $17.58 with 4,123,892 million shares trading.
CAI has a beta of 2.46, meaning it tends to be more sensitive to market movements. CAI has a correlation of 0.23 to the broad based SPY ETF.
CAI has a market cap of $5.04 billion. This is considered a Mid Cap stock.
Last quarter Caris Life Sciences reported $275 million in Revenue and $.05 earnings per share. This beat revenue expectation by $21 million and exceeded earnings estimates by $.03.
The top ETF exchange traded funds that CAI belongs to (by Net Assets): VTI, VB, VBK, VXF, IBB.
CAI has underperformed the market in the last year with a price return of -26.8% while the SPY ETF gained +6.9%. CAI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -28.5% and -30.3%, respectively, while the SPY returned -9.3% and -6.2%, respectively.
CAI support price is $17.59 and resistance is $19.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CAI shares will trade within this expected range on the day.